• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制增强子 zeste 同源物 2(EZH2)通过表观遗传调控 Yin Yang 1(YY1),引导与 T 细胞分化相关的转录因子,从而对抗非小细胞肺癌(NSCLC)。

Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC).

机构信息

Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, 603203, Tamil Nadu, India.

Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, 603203, Tamil Nadu, India.

出版信息

Med Oncol. 2023 May 22;40(7):185. doi: 10.1007/s12032-023-02053-2.

DOI:10.1007/s12032-023-02053-2
PMID:37212947
Abstract

Non-Small Cell Lung Cancer (NSCLC) is the leading cause of death in all countries alike. In the current study, we have found out that Histone H3Lys4trimethylation is abnormal on YY1 in CD4T Helper (T) cells of NSCLC patients which is evident by Histone H3Lys27 trimethylation mediated via EZH2. We investigated the status of Yin Yang 1 (YY1) and the involvement of certain transcription factors that lead to tumorigenesis after depleting endogenous EZH2 in vitro by CRISPR/Cas9 in the CD4T1-or-T2-polarized cells isolated initially as CD4T0 cells from the PBMC of the control subjects and patients suffering from NSCLC. After depletion of endogenous EZH2, RT-qPCR based mRNA expression analysis showed that there was an increase in the expression of T1 specific genes and a decrease in the expression of T2 specific genes in NSCLC patients CD4T cells. We can conclude that this group of NSCLC patients may have the tendency at least in vitro to elucidate adaptive/protective immunity through the depletion of endogenous EZH2 along with the reduction in the expression of YY1. Moreover, depletion of EZH2 not only suppressed the CD4CD25FOXP3Regulatory T cells (Treg) but also it aided the generation of CD8Cytotoxic T Lymphocytes (CTL) which were involved in killing of the NSCLC cells. Thus the transcription factors involved in EZH2 mediated T cell differentiation linked to malignancies offers us an appealing avenue of targeted therapeutic intervention for NSCLC.

摘要

非小细胞肺癌(NSCLC)是所有国家导致死亡的主要原因。在目前的研究中,我们发现 NSCLC 患者的 CD4T 辅助(T)细胞中的组蛋白 H3Lys4 三甲基化异常,这是通过 EZH2 介导的组蛋白 H3Lys27 三甲基化来证明的。我们研究了 Yin Yang 1(YY1)的状态以及某些转录因子的参与,这些转录因子在体外通过 CRISPR/Cas9 耗尽内源性 EZH2 后导致肿瘤发生,最初从对照受试者和患有 NSCLC 的患者的 PBMC 中分离出 CD4T0 细胞。在耗尽内源性 EZH2 后,基于 RT-qPCR 的 mRNA 表达分析显示,NSCLC 患者 CD4T 细胞中 T1 特异性基因的表达增加,而 T2 特异性基因的表达减少。我们可以得出结论,这组 NSCLC 患者至少在体外可能有通过耗尽内源性 EZH2 以及降低 YY1 的表达来阐明适应性/保护性免疫的倾向。此外,EZH2 的耗竭不仅抑制了 CD4CD25FOXP3Regulatory T 细胞(Treg),而且还促进了参与杀伤 NSCLC 细胞的 CD8Cytotoxic T Lymphocytes(CTL)的生成。因此,与恶性肿瘤相关的 EZH2 介导的 T 细胞分化涉及的转录因子为 NSCLC 提供了一种有吸引力的靶向治疗干预途径。

相似文献

1
Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC).抑制增强子 zeste 同源物 2(EZH2)通过表观遗传调控 Yin Yang 1(YY1),引导与 T 细胞分化相关的转录因子,从而对抗非小细胞肺癌(NSCLC)。
Med Oncol. 2023 May 22;40(7):185. doi: 10.1007/s12032-023-02053-2.
2
Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.癌症中zeste同源物2(EZH2)-阴阳1(YY1)轴的表观遗传调控
Pathol Res Pract. 2023 Nov;251:154885. doi: 10.1016/j.prp.2023.154885. Epub 2023 Oct 10.
3
Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.阴阳1介导的肿瘤抑制性微小RNA的表观遗传沉默激活肝细胞癌中的核因子κB
J Pathol. 2016 Apr;238(5):651-64. doi: 10.1002/path.4688.
4
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.EZH2与组蛋白去乙酰化酶的联合抑制作为非小细胞肺癌细胞的一种潜在表观遗传疗法。
Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.
5
Polycomb recruitment at the Class II transactivator gene.II类反式激活因子基因处的多梳蛋白招募
Mol Immunol. 2015 Oct;67(2 Pt B):482-91. doi: 10.1016/j.molimm.2015.08.003. Epub 2015 Aug 15.
6
Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases.阴阳1(YY1)表达在T细胞亚群分化及其功能中的作用:对T细胞介导疾病的影响
Crit Rev Immunol. 2019;39(6):491-510. doi: 10.1615/CritRevImmunol.2020033272.
7
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.EZH2 是治疗非小细胞肺癌的潜在靶点。
Cancer Med. 2019 Oct;8(14):6383-6392. doi: 10.1002/cam4.1855. Epub 2019 Aug 27.
8
Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.外泌体传递的长链非编码 RNA UFC1 通过 EZH2 介导的 PTEN 表达表观遗传沉默促进非小细胞肺癌进展。
Cell Death Dis. 2020 Apr 2;11(4):215. doi: 10.1038/s41419-020-2409-0.
9
FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.FOXC1 介导的 LINC00301 通过调节 HIF1α 通路促进非小细胞肺癌的肿瘤进展并触发免疫抑制微环境。
Genome Med. 2020 Sep 2;12(1):77. doi: 10.1186/s13073-020-00773-y.
10
Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.EZH2 是一种非小细胞肺癌的新型预后生物标志物。
Cancer. 2012 Mar 15;118(6):1599-606. doi: 10.1002/cncr.26441. Epub 2011 Aug 11.

引用本文的文献

1
Transcription factor Yin Yang 1 enhances epithelial-mesenchymal transition, migration, and stemness of non-small cell lung cancer cells by targeting sonic hedgehog.转录因子阴阳1通过靶向音猬因子增强非小细胞肺癌细胞的上皮-间质转化、迁移及干性。
Mol Cell Biochem. 2025 Mar;480(3):1831-1843. doi: 10.1007/s11010-024-05104-y. Epub 2024 Sep 11.

本文引用的文献

1
Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with polymorphisms: A systematic review and meta-analysis.酪氨酸激酶抑制剂治疗非小细胞肺癌患者的副作用及其与基因多态性的关联:一项系统评价和荟萃分析。
Oncol Lett. 2022 Dec 23;25(2):62. doi: 10.3892/ol.2022.13649. eCollection 2023 Feb.
2
Involvement of Xeroderma Pigmentosum Complementation Group G (XPG) in epigenetic regulation of T-Helper (T) cell differentiation during breast cancer.色素性干皮病互补群 G(XPG)在乳腺癌中 T 辅助(T)细胞分化的表观遗传调控中的作用。
Immunobiology. 2022 Sep;227(5):152259. doi: 10.1016/j.imbio.2022.152259. Epub 2022 Aug 22.
3
T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation bridges link between coronary artery disease and invasive ductal carcinoma.
T 辅助细胞介导的 RNA 甲基化中介的转录组学调控通过 m6A 将冠状动脉疾病与浸润性导管癌联系起来。
J Cancer Res Clin Oncol. 2022 Dec;148(12):3421-3436. doi: 10.1007/s00432-022-04130-x. Epub 2022 Jul 1.
4
Easy or Not-The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity.易或不易——EZH2 在调节抗肿瘤免疫中的 T 细胞发育、分化和激活方面的进展。
Front Immunol. 2021 Oct 19;12:741302. doi: 10.3389/fimmu.2021.741302. eCollection 2021.
5
R-loop modulated epigenetic regulation in T helper cells mechanistically associates coronary artery disease and non-small cell lung cancer.R环调节辅助性T细胞中的表观遗传调控,在机制上与冠状动脉疾病和非小细胞肺癌相关。
Transl Oncol. 2021 Oct;14(10):101189. doi: 10.1016/j.tranon.2021.101189. Epub 2021 Jul 31.
6
Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review.过去 10 年中,不同地区通过常规和新型方法检测非小细胞肺癌患者 EGFR 变异体的应用:系统评价。
Mol Biol Rep. 2021 Apr;48(4):3593-3604. doi: 10.1007/s11033-021-06379-w. Epub 2021 May 10.
7
Multiomic analysis of cytokines in immuno-oncology.免疫肿瘤学中细胞因子的多组学分析。
Expert Rev Proteomics. 2020 Sep;17(9):663-674. doi: 10.1080/14789450.2020.1845654. Epub 2020 Nov 23.
8
Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis.非小细胞肺癌患者接受酪氨酸激酶抑制剂治疗的多态性与生存率:一项系统评价和荟萃分析。
J Oncol. 2020 Mar 18;2020:1973241. doi: 10.1155/2020/1973241. eCollection 2020.
9
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?肿瘤微环境中的调节性 T 细胞(Treg 细胞):Treg 细胞能否成为新的治疗靶点?
Cancer Sci. 2019 Jul;110(7):2080-2089. doi: 10.1111/cas.14069. Epub 2019 Jun 18.
10
The role of cytokines in the regulation of NK cells in the tumor environment.细胞因子在肿瘤微环境中对 NK 细胞调节作用。
Cytokine. 2019 May;117:30-40. doi: 10.1016/j.cyto.2019.02.001. Epub 2019 Feb 18.